Shilpa Medicare's Recombinant Human Albumin 20% (rHA) is derived from yeast and offers a highly purified, structurally and ...

Shilpa Medicare Ltd announces that the results of its Phase I clinical trials were accepted by Subject Expert Committee ...

The rHA 20% product, derived from yeast, is a highly purified alternative to human serum albumin, matching it structurally ...

Through these partnerships, we're producing recombinant proteins like human serum albumin for cell culture media and ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of ...

Researchers have used machine learning and supercomputer simulations to investigate how tiny gold nanoparticles bind to blood proteins. The studies discovered that favorable nanoparticle-protein ...

The basic experimental model tested the ability of an infusion of human ... the infused albumin in the immediate postinfusion period a comparison was made between the rise in serum protein levels ...

Albumin human is derived from human plasma ... It increases blood plasma volume or serum albumin levels. Adult: IV- Acute hypovolemic shock- Initial: 25 g, adjust according to response.

In relation to the successful completion of Phase I clinical trials, Shilpa Medicare Ltd has announced that the Subject ...

Through these partnerships, we're producing recombinant proteins like human serum albumin for cell culture media and alpha-lactalbumin for nutritional uses, meeting critical health and wellness needs ...

Shilpa Medicare has informed that the subject expert committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval ...